Skip to main content
Keeping you afloat amidst the rising sea of regulations

Rare Pediatric Disease Clinical Trials Get New Lift from EMA-Inspired Gaucher Model

On December 6, 2017, FDA announced a new approach for pediatric disease drug development that the Agency believes will reduce the number of patients treated with a placebo and lead to more time-efficient product development. According to FDA Center for Drug Evaluation Director Janet Woodcock, M.D.,